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Objectives In this study, we evaluated the cellular origins and thrombogenic potential of microparticles.
Background Human atherosclerotic plaques contain submicron vesicles (microparticles) released during cell activation or
apoptosis.
Methods Microparticles were purified from plaques and platelet-free plasma from 26 patients undergoing carotid endar-
terectomy. Flow cytometry analysis revealed the presence of large amounts of microparticles in plaques but not
in healthy vessels.
Results Most plaque microparticles originated from leukocytes, of which 29  5% were macrophages, 15  3% lympho-
cytes, and 8  1% granulocytes. Plaques microparticles also derived from erythrocytes (27  4%), smooth mus-
cle (13  4%) and endothelial cells (8  2%), but not from platelets. Plaques from asymptomatic and symptom-
atic patients showed no differences in microparticle origins. Microparticles were at least 200-fold more
concentrated in plaque than in plasma. Plasma microparticles were primarily platelet-derived in contrast with
those of plaque and showed no smooth muscle cell origin. Both plaque and plasma microparticles exposed tis-
sue factor and generated thrombin, but this activity was twice as high in microparticles isolated from plaques,
reflecting the thrombogenic contribution of the individual classes of microparticles.
Conclusions These results demonstrate that microparticles are more abundant and more thrombogenic in human atheroscle-
rotic plaques than in plasma. The different cellular origins of plaque and plasma microparticles might explain
the increased thrombogenic activity of plaque microparticles. (J Am Coll Cardiol 2007;49:772–7) © 2007 by
the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.10.053M
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ctherosclerosis is a chronic inflammatory disease of the
essel wall resulting from the interaction between modified
ipoproteins, monocytes-macrophages, lymphocytes, and
ascular cells (1). The development and progression of
therosclerotic plaques are associated with apoptotic cell
eath (2). However, the local abundance of oxidized lipids
nd their antibodies affects apoptotic cell recognition by
acrophages, leading to the saturation of phagocytes with
ndigestible material (1,3) and local accumulation of cell
emnants. Indeed, membrane vesicles (microparticles
MPs]) shed by activated and apoptotic cells have been
dentified within the human atherosclerotic plaque (4).
rom the *INSERM Cardiovascular Research Center Lariboisière, Paris, France;
Department of Vascular Biology and Thrombosis Research, Medical University,
ienna, Austria; ‡Vascular Surgery Department, Beaujon Hospital, Clichy, France;
nd §Lariboisière Hospital, Paris, France. Supported by educational grants from
.R.I. Servier (Suresnes, France) and the European Vascular Genomics Network of
xcellence (LSHM-CT-2003-503254; Brussels, Belgium).t
Manuscript received April 24, 2006; revised manuscript received September 8,
006, accepted October 9, 2006.icroparticles, mostly of platelet origin, also circulate in the
lood, and their levels increase in patients with high
therothrombotic risk (5). We previously reported that
laque MPs bear tissue factor (TF) activity and expose
hosphatidylserine, a major determinant of their procoagu-
ant activity and clearance (6,7). We also observed that
laque MPs express lymphocyte and monocyte-macrophage
arkers but no platelet markers (7). However, no informa-
ion is available regarding the presence of MPs originating
rom other cell types and their relative importance. In this
tudy, we determined the cellular origins of MPs in both
therosclerotic plaque and blood from patients undergoing
ndarterectomy and investigate their respective procoagu-
ant activity.
aterials and Methods
atients. This study, approved by the hospital ethical
ommittee, included 26 patients undergoing carotid endar-
erectomy who gave their informed consent (Table 1).
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February 20, 2007:772–7 Microparticles and Human Atherosclerotic Plaquesicroparticle isolation. Surgical samples were rinsed in
terile phosphate-buffered saline and human plaques (758
00 mg) were isolated, minced in 0.2 m filtered Dulbecco’s
odified Eagles medium (volume corresponding to the
esion weight), and centrifuged at 400 g (15 min) and
2,500 g (5 min). The 12,500 g supernatant (plaque ho-
ogenate) was analyzed by flow cytometry, and MPs were
elleted at 20,500 g (150 min). A similar protocol was used
ith the vessel wall adjacent to the lesion (n  4) and with
uman internal mammary arteries (n  3). Platelet-free
lasma (PFP) was obtained from internal jugular vein and
arotid artery blood (8). Platelet-free plasma, homogenates,
nd MP pellets were stored at 80°C.
Specific cell-derived MPs were obtained after induction of
poptosis in human umbilical vein endothelial, human vascular
mooth muscle cells (SMCs) (Technoclone, Vienna, Austria)
nd the monocytic line U937 cells, using tumor necrosis
actor- (200 U/ml) and actinomycin-D (200 ng/ml).
icroparticles also were prepared from sedimented eryth-
ocytes stimulated with A23187 (5 mmol/l; 30 min). Plate-
et MPs were generated from a platelet pellet obtained
rom platelet-rich plasma, and stimulated with A23198
5 mol/l; 30 min).
lectron microscopy. Microparticles were fixed with glu-
araldehyde and osmium teroxide, dehydrated, and embed-
ed in Epon-Araldite. Sections contrasted with uranyl
cetate and lead citrate were examined with a Philips CM50
icroscope (Philips, Eindhoven, the Netherlands).
ellular origin of plaque and plasma microparticles.
nalyses were performed using selective fluorochrome-
abeled antibodies or their corresponding isotype-matched
mmunoglobulin G (IgG). Anti-CD4-phycoerythrin was
rovided by BD-Biosciences Pharmingen (San Jose, Califor-
ia); anti-CD31-phycoerythrin, anti-CD41-phycoerythrin-
yanin5, anti-CD62P-fuoroisothiocyanate, anti-CD66b-
uoroisothiocyanate, anti-CD144-phycoerythrin, and
nti-CD235a-fluoroisothiocyanate were obtained from
eckman-Coulter (Villepinte, France); and anti-CD14-
hycoerythrin was from Caltag Laboratories (Burlingame,
atients’ Baseline Characteristics (n  26)
Table 1 Patients’ Baseline Characteristics (n  26)
Age (yrs) 74 2
Male (%) 81
BMI (kg/m2) 25.0 0.5
Symptomatic plaques (%) (stroke, transient ischemic attacks) 50
Clinical features (%)
Diabetes 23
Hypertension 65
Smoking 31
Hypercholestorelomy 58
Treatments (%)
Antiaggregants 100
Statins 60
Angiotensin-converting enzyme inhibitors 36
Beta-blockers 20(MI  body mass index.alifornia). Microparticles ex-
ressing phosphatidylserine were
abeled using fluoroisothiocyanate-
onjugated AnnexinV (Roche
iagnostics, Paris, France) with
r without CaCl2 (5 mM).
mooth muscle cell actin (SMA)
as assayed after paraformalde-
yde fixation (2%), saponin per-
eabilization (0.1%), exposure
o rabbit anti-SMA (Labvision
td., New Market, Suffolk, En-
land), and AlexaFluor 555 don-
ey anti-rabbit IgGs (Molecular
robes, Inc., Eugene, Oregon).
issue factor–positive MPs were identified using anti-
uman TF antibody (American Diagnostica, Stamford,
onnecticut) and Alexa-fluor-488 goat anti-mouse IgG
Molecular Probes).
Microparticles were analyzed on a Beckman-Coulter
PICS XL flow cytometer in the presence of Flowcount
alibrator beads. Microparticle gate was defined as events
ith a 0.1- to 1-m diameter and examined on a fluores-
ence/forward light scatter plot.
hrombin generation assay. Microparticles (103 to 105)
ere mixed with fluorogenic thrombin substrate Z-Gly-
ly-Arg-AMC (1 mmol/l; Bachem, Bubendorf, Switzer-
and) in the presence of calcium (Technothrombin Tech-
oclone, Vienna, Austria). Thrombin formation was
nitiated by normal human MP-free plasma and monitored
sing a Microplate Fluorescence Reader (Wallac/
erkinElmer, Turku, Finland). The rate of increase in
uorescence intensity (fluorescence units [FU]) was calcu-
ated every min (FU/min), and converted to thrombin
oncentrations (nmol/l) using a reference curve obtained
ith purified thrombin.
tatistical analysis. Microparticle levels were expressed as
edian and range and analyzed using nonparametric
ann-Whitney U tests. Thrombin-generating activity
TGA) data were expressed as mean  SEM, according to
he distribution normality, and analyzed by analysis of
ariance followed by Bonferonni post-test (StatView4.51,
AS Institute, Cary, North Carolina). Differences were
ignificant at p  0.05.
esults
ellular origin of human atherosclerotic plaque MPs.
icroparticles were detected in human plaque homogenates
y calcium-dependent AnnexinV labeling and electron mi-
roscopy analysis (Figs. 1A to 1C). Large amounts of
nnexinV-positive MPs were found in plaques and almost
one in human mammary arteries, indicating that micro-
articles were not generated by the isolation procedure
Abbreviations
and Acronyms
IgG  immunoglobulin G
MPs  microparticles
PFP  platelet-free plasma
RBC  red blood cell
SMA  smooth muscle cell
actin
SMC  smooth muscle cell
TF  tissue factor
TGA  thrombin-generating
activityMann-Whitney U test, p  0.0001) (Fig. 2).
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Microparticles and Human Atherosclerotic Plaques February 20, 2007:772–7Human atherosclerotic plaques contained detectable levels
f MPs derived from lymphocytes (CD4), macrophages
CD14), granulocytes (CD66b), endothelial cells
CD144), erythrocytes (CD235a), and SMC (SMA)
Fig. 3). The majority of plaque MPs originated from
eukocytes (52  9%), of which 29  5% were from mac-
ophages, 15  3% from lymphocytes, and 8  1% from
ranulocytes (Fig. 4). No CD31/CD41 or CD62P/
D144-MPs were detected, indicating that platelet-derived
Ps were below detectable levels in human plaques. Mi-
roparticle levels and cellular origin were unchanged be-
ween symptomatic and asymptomatic plaques (Table 2).
Figure 1 Plaque Microparticle Identification by Electron Micros
Electron microscopy (A) and cytofluorometry analysis (B and C). (B) Plaque micro
ter (FS)/side scatter (SS) logarithmic representation. Microparticles are defined as
of size-selected events versus fluorescence for AnnexinV-FITC binding (FL1). The ye
Figure 2 AnnexinV-Positive MPs
AnnexinV-positive macroparticle (MP) levels in plaque compared with the arterial w
microparticles isolated from human mammary arteries (n  3) using the same isoirculating MPs from endarterectomized patients.
omparable levels of AnnexinV-positive MPs were de-
ected in venous and arterial PFPs (1,196  267 per l vs.
,881 562 per l, respectively; p 0.55), whereas plaques
ontained 323  63 AnnexinV-positive MP/g. Because
laques were homogenized in a volume corresponding to
he lesion weight, we can assume that 1 mg of plaque
orresponds to 1 l of plasma, indicating that AnnexinV-
ositive MPs were at least 200-fold more abundant in
esions than in plasma.
Most circulating MPs were derived from platelets and
rythrocytes (Fig. 3). Microparticle subtypes were similar
and Cytofluorometry Analysis
s and calibrator beads (CAL) (10 m diameter) are visualized in a forward scat-
s (size 0.1 to 1 m) gated in the “B” window. (C) Representative FL1 histogram
eak corresponds to negative control.
acent to the lesion (n  4) and to
procedure. *p  0.0001 (Mann-Whitney U test).copy
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February 20, 2007:772–7 Microparticles and Human Atherosclerotic Plaquesetween venous and arterial samples (Fig. 3). However,
he plasma MP population was very different from that
ound in atherosclerotic lesions because plaque contained
Ps derived from SMCs but not from platelets, whereas
lasma MPs were platelet-derived but not SMC-derived
Fig. 4).
rothrombogenic activity. Tissue factor expression was
omparable between plaque (58  2%) and circulating MPs
68  20%) and between symptomatic and asymptomatic
laques (not shown). Plaque MP TGA was approximately
wice that of circulating MPs (Bonferonni p  0.006, 3
omparisons) (Figs. 5A to 5C) but was unchanged between
ymptomatic (167  63 nmol/l) and asymptomatic patients
234  68 nmol/l), as was arterial and venous microparticle
GA. When TGA was measured using isolated cell-
Figure 3 Cellular Origin of Plaque MPs
Microparticle (MP) distribution and cellular origins in human plaque (A), venous
plasma (B), and arterial plasma (C) (n  26). Data are given as median (hori-
zontal bar), 25th and 75th percentile (boxes), and 90th percentile (error bar).
Endoth.  endothelial cell origin; Granul.  granulocyte origin; Lymph.  lym-
phocyte origin; Mac.  macrophage origin; Platel.  platelet origin; RBC  red
blood cell origin; SMC  smooth muscle cell origin.erived MPs, the thrombin peak was highest forndothelial-, smooth muscle- and red blood cell-derived
Ps but was significantly lower for monocyte and platelet
rigins (analysis of variance, p  0.001; Bonferonni 10
omparisons) (Fig. 5D).
iscussion
icroparticles present in human atherosclerotic lesions
rigger thrombus formation at the time of plaque rupture
hen they get in contact with plasma coagulation factors
7,9). This study depicts for the first time the cellular origins
f MPs present in human atherosclerotic lesions and dem-
nstrates that plaque MPs mainly originate from macro-
hages, erythrocytes, and SMCs. In this regard, their
ellular origins are distinct from their plasma counterpart
ecause the latter are derived mainly from platelets, indi-
ating that circulating MPs are unlikely to result from
uptured plaques. We also demonstrate that MPs are more
bundant and more thrombogenic in plaque than in plasma,
feature resulting from their differences in cellular origin.
We describe here a procedure to isolate MPs from human
therosclerotic plaques, where their presence has been docu-
ented earlier (4,7). Most of these MPs were derived from
ctivated leukocytes, a hallmark of inflammation, and from
rythrocytes, revealing the occurrence of intraplaque hemor-
hages. Although erythrocytes are enucleated and lack mito-
hondria, they can undergo a rapid self-destruction process
esembling apoptosis (10). Platelet MPs are absent from
therosclerotic lesions (7), possibly because of selective removal
f platelets by phagocytes (11). Atherosclerotic plaques also
ontained MPs derived from SMCs, in agreement with the
Figure 4 Comparison of Cellular Origins of
Circulating and Plaque Human Microparticles
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Median values and range are expressed as numbers per microgram lesion.
MP  microparticle; SMA  smooth muscle cell actin; SMC  smooth mu
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Microparticles and Human Atherosclerotic Plaques February 20, 2007:772–7resence of apoptotic SMCs and SMC-derived remnants in
uman lesions (4,12). Finally, human plaques also contained
ndothelial MPs, possibly originating from apoptotic luminal
ells (13) or from activated and/or injured endothelial cells of
ntraplaque microvessels, resulting in microvessel leakiness and
ntraplaque hemorrhage.
Although there was a trend toward greater numbers of
Ps of different cellular origins in symptomatic plaque, this
rend did not reach statistical significance. However, we
annot exclude the possibility that MPs might have been
eleased at the time of rupture, leading to an underestima-
ion of MP abundance before this event. Unlike plaque
Ps, plasma MPs from patients undergoing endarterec-
omy mainly were derived from platelets, erythrocytes, and
onocytes, which is in agreement with previous reports
5,8). Thus, the present study clearly demonstrates that
ost circulating MPs do not result from ruptured plaques
nd that they must be generated within the blood compart-
ent or at the vessel-wall interface.
Plaque MPs were more thrombogenic than their circu-
ating counterparts possibly because plaques contain highly
hrombogenic SMC-derived MPs, whereas circulating
Ps, which were derived mainly from platelet but not from
MC, have lower thrombin-generating potential. Indeed,
urified endothelial, SMC, and erythrocyte MPs displayed
eak thrombin generation significantly higher than mono-
yte and platelet-derived MPs. However, the protrombo-
enic activity of plaque microparticles may be limited in vivo
y the fact that only a fraction of these MPs would
articipate in thrombosis in the event of plaque rupture.
bviously, this point will require further study.
onclusions. This first report characterizing the cellular
rigins of human plaque MPs demonstrates that they derive
ainly from macrophages, erythrocytes, and SMCs and that
Ps are more concentrated and more thrombogenic in
uman atherosclerotic plaque than in the corresponding
lasma in part because they include highly thrombogenic
MC-derived MPs.
cknowledgments
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